Dermapharm off to an excellent start to financial year 2022

Grünwald, 1 June 2022 - Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today successfully held its 2022 Annual General Meeting. 80.43% of the share capital was in attendance at the virtual Annual General Meeting. The majority of shareholders approved the management's proposals under every agenda item.

Grünwald, 18 May 2022 - Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, increased its consolidated revenue by 9.1% to EUR 231.6 million in the first quarter of financial year 2022 (prior-year period: EUR 212.2 million).

Grünwald, 12 April 2022 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its full Annual Report 2021. Dermapharm confirms its preliminary consolidated figures (IFRS) for financial year 2021. Both consolidated income and adjusted consolidated EBITDA rose to record highs in financial year 2021. Growth was driven by the rise in demand for products to strengthen the immune system, allergology products, and the cooperation agreement with BioNTech SE to manufacture the Comirnaty® vaccine.